文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性前列腺癌中[18F]DCFPyL与[18F]FAPI-74 PET/CT成像的比较

Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-26

这项前瞻性研究纳入39例转移性前列腺癌患者,在两周内分别接受[18F]DCFPyL(PSMA)和[18F]FAPI-74(FAPI)全身PET/CT,比较两种靶向示踪剂的病灶检出能力与肿瘤负荷。结果显示PSMA PET/CT检出99%的病灶,而FAPI仅检出58%(PSMA引导分析)或38%(独立分析),PSMA病灶SUVmax中位数显著更高,提示PSMA PET/CT仍是首选的分子成像方法,FAPI诊疗一体化作用有限。

要点

  • PSMA PET/CT检出99%病灶,FAPI仅58%,PSMA为优选方法
  • PSMA病灶SUVmax中位数24,显著高于FAPI的5.4
  • 仅1%病灶为FAPI阳性且PSMA阴性,FAPI治疗价值有限

核心结论

  • 在转移性前列腺癌中,PSMA PET/CT仍是首选的分子成像方法,FAPI放射性配体治疗作用有限。
  • FAPI诊疗一体化应聚焦于内脏转移及腺泡腺癌以外的特定组织学亚型患者。

研究设计与样本

  • 患者均在两周内接受长轴视野全身[18F]DCFPyL和[18F]FAPI-74 PET/CT。
  • 按预设标准阅片,每个解剖区域最多评估5个转移灶,病灶分为骨、盆腔淋巴结、盆腔外淋巴结或内脏四组。

主要发现

  • 39例患者共识别1365个病灶,[18F]DCFPyL PET/CT检出1351个(99%)。
  • [18F]FAPI-74在PSMA引导分析中仅检出788个(58%)病灶,独立分析中检出523个(38%)。
  • 病灶SUVmax中位数PSMA为24,高于FAPI的5.4(p < 0.001)。
  • 两种示踪剂中内脏转移均占病灶的3%,FAPI摄取倾向更高(64%)。
  • 仅14个(1%)病灶为FAPI阳性且PSMA阴性。

临床怎么用

  • 转移性前列腺癌的分子成像应优先选择PSMA PET/CT。
  • FAPI放射性配体治疗不宜作为转移性前列腺癌的常规策略,可考虑用于内脏转移或非腺泡腺癌亚型患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare prostate-specific membrane antigen (PSMA) and fibroblast activation-protein inhibitor (FAPI) targeted PET/CT imaging to assess possible theranostic combination strategies of both tracers in metastatic prostate cancer (mPC). METHODS: This prospective study enrolled patients with mPC who underwent long-axial field-of-view whole-body PET/CT with 18F-DCFPyL and 18F-FAPI-74 within two weeks. Fifteen patients had hormone sensitive (mHSPC) and 24 castration-resistant (mCRPC) disease. Scans were reviewed according to predefined criteria, with up to five metastases per anatomical region evaluated. Lesions were categorized in four groups as skeletal, pelvic nodal, extrapelvic nodal, or visceral. SUVmax and volumetric parameters were measured for each lesion and at the patient level. RESULTS: A total of 1365 lesions were identified in 39 patients. 18F-DCFPyL PET/CT detected 1351 lesions (99%). In contrast, 18F-FAPI-74 identified only 788 (58%) lesions in the PSMA-guided analysis and 523 (38%) lesions in the independent analysis. Median lesion SUVmax was higher for PSMA (24) than for FAPI (5.4) (p < 0.001). Visceral metastases constituted 3% of lesions with both tracers and tended to be more often FAPI-avid (64%) compared to other lesion groups. Only 14 (1%) of lesions were FAPI-positive and PSMA-negative. In whole-tumor burden analysis, median tracer-positive tumor volume on 18F-DCFPyL PET/CT was 85 mL and on 18F-FAPI-74 PET/CT only 10 mL (p < 0.001). CONCLUSION: In mPC, PSMA PET/CT remains the preferred molecular imaging method. Our findings suggest only a limited role of FAPI radioligand therapy. FAPI theranostics should focus on patients with visceral metastases and specific histological subtypes beyond acinar adenocarcinoma. CLINICAL TRIAL REGISTRATION: EUDRACT: 2022-003788-13. Registered 21 September 2023.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hyväkkä A, Seppänen M, Sundvall M, et al. Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42350616. doi:10.1007/s00259-026-08028-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。